Core-shell heterostructured nanozyme for alveolar echinococcosis treatment via targeted electron transfer and catalytic reactive oxygen species generation.

pH/pectinase dual-responsive pectin-chitosan nanoparticles for pathogen-activated delivery of α-Terthienyl against Botrytis cinerea.

Nano-delivery system of milk-derived exosomes loaded with Forsythiaside A: Studies on bovine mammary epithelial cells and mastitis induced mice.

ROS and the cell cycle: Cycling in and out of the comfort zone of redox control.

A precise theranostic nanoplatform amplifies anti-tumor efficacy via copper ionophores and sonodynamic therapy.

ROS-mediated therapeutic approach through oxidative stress and cell signalling modulation.

Single-pore silica nanotherapeutic platform with pH-Responsive NO release for osteoporosis repair.

Mechanistic exploration of methylglyoxal-induced hepatotoxicity involving oxidative stress, apoptosis, and gluconeogenic modulation.

Vitisin B rejuvenates senescence via WBP2NL regulation.

Modulated oxidation pathways enabled by CoFe bimetallic alloy catalysts for effective elimination of antibiotics.

Imeglimin is a first-in-class oral antidiabetic that enhances glucose-induced insulin secretion and improves insulin resistance. Although imeglimin has been shown to exert protective effects on β-cells and hepatocytes partly by reducing the production of reactive oxygen species, its renoprotective effects remain largely unknown. In this study, we evaluated the effects of imeglimin on the kidneys using a mouse model of acute kidney injury induced by ischemia-reperfusion injury. Imeglimin significantly attenuated the increase in serum creatinine and blood urea nitrogen levels, as well as histological kidney injury. Gene ontology analysis of differentially expressed genes identified by RNA-sequencing of kidney tissues revealed that pathways related to inflammation were enriched in genes downregulated by imeglimin, whereas lipid metabolism and regulation of sodium ion transport were among the top enriched categories for genes upregulated by imeglimin. Moreover, ischemia-induced increase in the number of γH2AX-positive nuclei in proximal tubules was significantly suppressed by imeglimin. In addition, imeglimin inhibited increase in reactive oxygen species levels in human proximal tubule cells induced by transient hypoxia. These results indicate that imeglimin protects the kidney from ischemia-reperfusion injury by attenuating inflammatory responses and DNA damage, thereby maintaining gene expression associated with renal function. This protective effect may be partly mediated by a reduction in reactive oxygen species production. The potential of imeglimin to provide clinically meaningful protection against kidney complications warrants further investigation, considering the protective effects observed in ischemia-reperfusion injury.

Investigating the therapeutic potential of nasal administration of mitochondria on blood-brain barrier integrity and vasogenic brain Edema in a rat ischemic stroke model.

Nrf2: the key target for antagonizing the toxicity of deoxynivalenol.

Co-exposure to polystyrene nanoplastics and hexachlorocyclohexane induces enhanced human sperm toxicity in vitro.

A bilirubin-gold nanoconjugate photosensitizer for photothermal/photodynamic therapy of HeLa cells through glutathione depletion and ROS generation.

Oral delivery of engineered Lactococcus lactis microcapsules expressing antioxidant enzymes for inflammatory bowel disease: Mechanisms of intestinal barrier repair and microbiota modulation.

A multifunctional and ROS response CO-gas delivery platform for spinal cord regeneration.

The intelligent nanoreactor ignites mitochondrial homeostasis disruption via calcium overload and ROS storm for the treatment and visual diagnosis of lung adenocarcinoma.

Cascade ROS-modulating Au/Cu nanozyme hydrogel with nitric oxide release ability for accelerated diabetic foot ulcer healing.

Parkinson's disease (PD), the second most common neurological disorder, is often managed with medications targeting specific symptoms. Complementing conventional therapies, medicinal plants are frequently used for neurological disorders, including PD. This study evaluated the effects of crude extracts and fractions of Catha edulis (Vahl) Forssk. ex Endl. and Datura stramonium L.-psychoactive plants-on PD-related mechanisms using SH-SY5Y human neuroblastoma cells. Crude extracts of C. edulis (leaves) and D. stramonium (leaf/root mixture) were prepared using dichloromethane/methanol (50/50). Fractionation was performed via C8 solid-phase extraction. Cytotoxicity and cytoprotective effects of the crude extracts and fractions against 6-hydroxydopamine-induced cytotoxicity were assessed using the sulforhodamine B assay. Mechanistic studies included reactive oxygen species (ROS) generation, mitochondrial integrity, and apoptosis assays. In silico analysis was used to assess the binding of biomarkers to dopamine receptors. Both plant extracts exhibited minimal cytotoxicity. Crude extracts and fractions (F1-F7) displayed cytoprotective effects (5.8-34.28%). The highest ROS reduction was observed for F1 of C. edulis (1.72-fold) and F2 of D. stramonium (1.33-fold). Both extracts reduced caspase 3/7 activation and maintained mitochondrial integrity. Atropine and scopolamine showed cytoprotection with IC50 values of 49.48μM and 48.26μM, respectively. In silico analysis indicated strong binding affinities of norephedrine and noradrenaline to dopamine D1 and D2 receptors. Both plant extracts preserved cell viability, reduced ROS levels, and maintained mitochondrial integrity, highlighting their potential as therapeutic agents for PD.